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Background: Recurrence is the most common complication of peri-
carditis, affecting 10% to 50% of patients.
Objective: To evaluate the efficacy and safety of colchicine for the
secondary prevention of recurrent pericarditis.
Design: Prospective, randomized, double-blind, placebo-
controlled multicenter trial. (ClinicalTrials.gov registration num-
ber: NCT00128414)
Setting: 4 general hospitals in urban areas of Italy.
Patients: 120 patients with a first recurrence of pericarditis.
Intervention: In addition to conventional treatment, patients were
randomly assigned to receive either placebo or colchicine, 1.0 to
2.0 mg on the first day followed by a maintenance dose of 0.5 to
1.0 mg/d, for 6 months.
Measurements: The primary study end point was the recurrence
rate at 18 months. Secondary end points were symptom persis-
tence at 72 hours, remission rate at 1 week, number of recurrences,
time to first recurrence, disease-related hospitalization, cardiac tam-
ponade, and rate of constrictive pericarditis.
Results: At 18 months, the recurrence rate was 24% in the col-
chicine group and 55% in the placebo group (absolute risk reduc-
tion, 0.31 [95% CI, 0.13 to 0.46]; relative risk reduction, 0.56 [CI,
0.27 to 0.73]; number needed to treat, 3 [CI, 2 to 7]). Colchicine
reduced the persistence of symptoms at 72 hours (absolute risk
reduction, 0.30 [CI, 0.13 to 0.45]; relative risk reduction, 0.56 [CI,
0.27 to 0.74]) and mean number of recurrences, increased the
remission rate at 1 week, and prolonged the time to subsequent
recurrence. The study groups had similar rates of side effects and
drug withdrawal.
Limitation: Multiple recurrences and neoplastic or bacterial causes
were excluded.
Conclusion: Colchicine is safe and effective for secondary preven-
tion of recurrent pericarditis.
Primary Funding Source: Maria Vittoria Hospital, Torino, Italy.
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Recurrent pericarditis is probably the most common andtroublesome complication of acute pericarditis, occur-
ring in 10% to 30% of patients with a first episode of acute
pericarditis (1–3). The recurrence rate increases up to 50%
after a first recurrence (4). Colchicine has shown promise
for the secondary prevention of recurrent pericarditis in
observational studies (5–7) and in the CORE (COlchicine
for REcurrent pericarditis) trial (4), an open-label, single-
center, randomized trial in which the drug halved the re-
currence rate. Low dosages of colchicine (0.5 to 1.0 mg/d)
seem to be safe and effective for treating pericarditis (1, 4,
8). However, no multicenter, double-blind, randomized
trial has confirmed these favorable preliminary findings.
The aim of the CORP (COlchicine for Recurrent Pericar-
ditis) trial is to evaluate the efficacy and safety of colchicine
as an adjunct to conventional therapy for the secondary
prevention of recurrence in patients with a first recurrence
of pericarditis (9).
METHODS
The CORP trial is a prospective, randomized, double-
blind, placebo-controlled, multicenter trial to evaluate the
efficacy and safety of colchicine for the treatment and pre-
vention of recurrent pericarditis. Colchicine was consid-
ered as an adjunct to conventional therapy (9).
Setting and Participants
We enrolled 120 patients with a first recurrence of
pericarditis from 4 general hospitals in Italy (Maria Vitto-
ria Hospital, Torino; Ospedali Riuniti, Bergamo; San
Maurizio Regional Hospital, Bolzano; and Ospedale SS
Annunziata, Savigliano). All consecutive patients with a
first recurrence of pericarditis were assessed for potential
enrollment. Pericarditis was diagnosed by using available
published criteria (1, 4, 10, 11), which include typical peri-
cardial chest pain, pericardial friction rubs, widespread ST-
segment elevation or PR-segment depression that was not
previously reported, and new or worsening pericardial ef-
fusion on echocardiography. A clinical diagnosis of acute
pericarditis was made when at least 2 of these criteria were
present (11). Recurrence was documented in patients who
had recurrent chest pain and 1 or more of the following
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signs: fever; pericardial friction rubs; electrocardiographic
changes; echocardiographic evidence of new or worsening
pericardial effusion; or elevated leukocyte count, erythro-
cyte sedimentation rate, or C-reactive protein level (4). Pa-
tients were eligible if they had no contraindication to col-
chicine therapy, could provide informed consent, and had
a favorable short-term prognosis. Inclusion criteria were a
definite diagnosis of recurrent pericarditis (first recur-
rence), age 18 years or older, and provision of informed
consent. The relevant institutional review boards and eth-
ics committees approved our research protocol, and all par-
ticipants gave written informed consent.
Patients were excluded if they were having their first
episode of acute pericarditis or their second or subsequent
recurrence or had pericarditis with tuberculous, purulent,
or neoplastic causes; known severe liver disease; current
aminotransferase levels greater than 1.5 times the upper
limit of normal, current serum creatinine level greater than
221 mol/L (2.5 mg/dL); known myopathy; serum crea-
tine kinase level above the upper limit of normal; known
blood dyscrasias; gastrointestinal disease; or known hyper-
sensitivity to colchicine. Also excluded were pregnant or
lactating women (because of the contraindication to col-
chicine) and women in their childbearing years who were
not using contraception. Finally, we excluded persons who
were receiving or had previously received colchicine for any
indication.
Random Assignment and Interventions
Participants were randomly assigned to treatment
groups by a central computer–based automated sequence.
Randomization was based on permuted blocks, with a
block size of 4. The random allocation sequence was im-
plemented by using sequentially numbered containers. All
participants and trial investigators were blinded to ran-
domized treatment. Colchicine tablets contained 1 mg of
the active drug. All tablets were identical in color, shape,
and taste; premarked to allow splitting into 2 equal parts;
and provided in blister packs. Unblinded data were made
available exclusively to an independent data and safety and
monitoring board in the event of severe side effects. Data
were collected by using case report and clinical events ad-
judication forms and were managed by investigators who
were blinded to treatment assignments. A blinded clinical
end point committee adjudicated all events.
Patients were randomly assigned to receive placebo or
colchicine in addition to conventional treatment with as-
pirin, 800 to 1000 mg (or ibuprofen, 600 mg) orally every
8 hours for 7 to 10 days, with gradual tapering over 3 to 4
weeks. Patients received colchicine, 1.0 to 2.0 mg, on the
first day, followed by a maintenance dosage of 0.5 to 1.0
mg/d for 6 months; all dosages were given as 2 doses 12
hours apart. Patients who weighed less than 70 kg or could
not tolerate the highest dosage (2.0 mg followed by 1.0
mg/d) received a lower dosage (0.5 mg every 12 hours,
followed by 0.5 mg once daily). Gastrointestinal intoler-
ance is a common cause of drug withdrawal. If symptoms
of gastrointestinal intolerance (diarrhea, nausea, cramping,
abdominal pain, or vomiting) persisted, the investigators
could prescribe halving the dosage (by splitting the tablets)
Table 1. Baseline Participant Characteristics
Characteristic Placebo Group
(n  60)
Colchicine Group
(n  60)
Mean age (SD), y 47.3 (14.4) 47.9 (15.4)
Men, n (%) 29 (48) 34 (43)
Current smokers, n (%) 25 (42) 26 (56)
Hypertension, n (%) 15 (25) 12 (20)
Diabetes mellitus, n (%) 1 (2) 2 (3)
Chronic obstructive pulmonary
disease, n (%)
2 (3) 2 (3)
Creatinine clearance 60 mL/min
per 1.73 m2, n (%)*
2 (3) 4 (7)
Hypothyroidism, n (%) 1 (2) 2 (3)
Previous idiopathic cause, n (%) 48 (80) 50 (83)
Previous autoimmune cause,
n (%)†
12 (20) 10 (17)
Previous use of corticosteroids,
n (%)
6 (10) 5 (8)
Previous cardiac surgery, n (%) 4 (7) 3 (5)
Previous myocardial infarction,
n (%)
6 (10) 7 (12)
Mean time from first episode
(SD), mo
6.1 (4.9) 6.8 (4.0)
Fever, n (%) 19 (32) 18 (30)
Pericarditic chest pain, n (%) 60 (100) 60 (100)
Pericardial rub, n (%) 13 (22) 12 (20)
Pericardial effusion, n (%) 35 (58) 36 (60)
Mean ejection fraction (SD), % 58 (4.2) 58 (6.2)
Elevated C-reactive protein level,
n (%)‡
54 (90) 57 (95)
Concomitant anti-inflammatory
therapy, n (%)
Aspirin or ibuprofen 55 (92) 56 (93)
Prednisone 5 (8) 4 (7)
* Using the Cockroft–Gault equation; refers to the first episode of acute
pericarditis.
† Includes inflammatory systemic diseases and postpericardiotomy syndromes.
‡ Defined as 95.2 nmol/L.
Context
Patients who have a recurrence of pericarditis are at high
risk for subsequent episodes. Evidence regarding effective
treatment and prevention are lacking.
Contribution
In this study, colchicine hastened the resolution of recur-
rent pericarditis and reduced the number of further
recurrences.
Caution
Only patients with a first recurrence of pericarditis were
studied.
Implication
Colchicine is useful for treatment and prevention after a
first recurrence of pericarditis.
—The Editors
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without unmasking the randomization code. Therapy was
discontinued if symptoms persisted at the lower dosage.
The prescribed dosages of colchicine are based on previous
studies (1, 4) that showed reduced side effects and im-
proved drug tolerability compared with maintenance doses
greater than 1.0 mg/d.
Additional medical therapies were initiated on the ba-
sis of comorbid conditions (Table 1), existing practice
guidelines, and local practice. Concomitant aspirin or ibu-
profen was the first-choice anti-inflammatory medication.
Patients with contraindications to aspirin (allergy, history
of peptic ulcer or gastrointestinal bleeding, or a high or
unacceptable risk for bleeding due to oral anticoagulant
therapy) or who had aspirin intolerance received predni-
sone, 0.2 to 0.5 mg/kg of body weight per day for 4 weeks
(12), and then the dosage was gradually tapered. When
aspirin or another nonsteroidal anti-inflammatory drug
was prescribed as combination therapy with placebo or col-
chicine, the patient also received a proton-pump inhibitor
for gastroduodenal prophylaxis (9).
Outcomes and Follow-up
The primary study end point was the recurrence rate
at 18 months. The secondary end points were symptom
persistence at 72 hours, remission rate at 1 week, number
of recurrences, time to first recurrence, disease-related hos-
pitalization, cardiac tamponade, and rates of constrictive
pericarditis. A blinded clinical end point committee adju-
dicated all end points.
Criteria for recurrence were the same as those for di-
agnosis of the first recurrence. Patients were considered to
have remission when they were symptom-free and had no
clinical, electrocardiographic, or echocardiographic signs of
disease (1, 4). Treatment failure was considered if an un-
favorable clinical reaction occurred, such as persistence of
fever, appearance or worsening of pericardial effusion, or
general illness lasting more than 7 days from the beginning
of treatment (1, 4, 9). Regularly scheduled study follow-up
visits were performed at 1 week, 1 month, 3 months, 6
months, 12 months, and 18 months and included a med-
ical visit; electrocardiography; echocardiography; blood
chemistry with complete blood count; and assessment of
C-reactive protein, creatinine, aminotransferase, and crea-
tine levels.
Safety
During follow-up, all adverse events were monitored
and recorded. An adverse event was considered severe if it
was fatal or life-threatening, required hospitalization, or
was significantly or permanently disabling or medically sig-
nificant (that is, it could have jeopardized the patient or
required medical or surgical intervention to prevent an ad-
verse outcome). An adverse event was filed according to
whether it was discovered by patient-reported symptoms or
blood chemistry monitoring during follow-up visits. A
safety monitoring committee whose members were masked
to treatment assignment did an interim analysis after 60
participants (50%) were enrolled. Unmasking of the ran-
domization code was allowed only when severe adverse
events occurred.
Statistical Analysis
We needed 120 patients, 60 in each treatment group,
to detect a 50% relative reduction in the risk for recurrence
(50% in the placebo group vs. 25% in the colchicine
group) with a power of 80%, using a 2-sided  value of
0.05. The estimated 50.0% rate of recurrent pericarditis in
the placebo group was based on the preliminary findings of
the CORE trial (4). Analyses were performed by intention
to treat.
Data were expressed as means (SDs). Patient groups
were compared by using the Mann–Whitney test for con-
tinuous variables and a chi-square analysis for categorical
variables. A P value less than 0.05 indicated statistical sig-
nificance. Time-to-event distributions were estimated by
using the Kaplan–Meier method and compared by using
the log-rank test. Analyses were performed with SPSS, ver-
sion 13.0 (SPSS, Chicago, Illinois).
Role of the Funding Source
Our trial was an independent study founded and per-
formed in the Italian National Healthcare System. The
steering committee designed and oversaw the trial and had
the final decision on the contents of the manuscript. All
data were received, checked, and analyzed independently at
the cardiology department of Maria Vittoria Hospital,
Torino, Italy, after blinded adjudication of clinical events
Figure 1. Study flow diagram.
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and side effects. Acarpia (Madeira, Portugal) provided the
drug and placebo as an unrestricted grant.
RESULTS
Patients were recruited between August 2005 and
April 2009, and the trial was completed in October 2010
after the last planned follow-up (18 months after random
assignment of the last enrolled patient). Baseline patient
characteristics were similar between the 2 study groups
(Table 1). Figure 1 shows a detailed flow diagram of the
study.
All patients who tolerated treatment with colchicine or
placebo discontinued therapy at 6 months, as planned. No
open-label colchicine was administered after the end of the
experimental treatment. No patient was lost to follow-up,
and all participants were analyzed for outcomes according
to their original assigned groups.
At 18 months, the recurrence rate was 24% in the
colchicine group and 55% in the placebo group (absolute
risk reduction, 0.31 [95% CI, 0.13 to 0.46]; relative risk
reduction, 0.56 [CI, 0.27 to 0.73]; number needed to
treat, 3 [CI, 2 to 7]). Colchicine also significantly reduced
the persistence of symptoms at 72 hours (absolute risk re-
duction, 0.30 [CI, 0.13 to 0.45]; relative risk reduction,
0.56 [CI, 0.27 to 0.74]) and the mean number of recur-
rences, increased the remission rate at 1 week, and pro-
longed the time to recurrence (Table 2). During a mean
follow-up of more than 20 months, no cases of constrictive
pericarditis occurred in the study groups. Figure 2 shows
the recurrence-free survival rate by treatment group.
The colchicine and placebo groups had similar rates of
side effects (7% vs. 7%; P  0.99) and drug withdrawal
(8% vs. 5%; P  0.89). No severe side effects occurred. All
side effects were recorded in the first week of treatment.
Gastrointestinal intolerance was the main side effect during
the study (7% in the colchicine group and 5% in the
placebo group), although 1 case of hepatotoxicity (2%)
related to concomitant hepatobiliary tract disease was ob-
served in the placebo group.
Colchicine therapy was discontinued in 5 patients
(8%). A medical decision was the main cause of drug with-
drawal in 4 of these cases (80%), as well as for all cases in
the placebo group. Table 3 lists side effects and drug with-
drawal data.
DISCUSSION
In the CORP trial, colchicine as an adjunct to con-
ventional anti-inflammatory therapy halved the recurrence
rate of pericarditis at 18 months after a first episode re-
duced the number of recurrences, and prolonged the time
to subsequent recurrence, with no significant or severe side
effects. The placebo and treatment groups had similar rates
of side effects, with gastrointestinal intolerance (the main
side effect) occurring in up to 7% of cases. To our knowl-
edge, this is the first multicenter, double-blind, random-
ized trial to show such efficacy and safety for colchicine.
The exact mechanism of the therapeutic and preven-
tive effects on pericarditis is not fully understood. Most of
the pharmacologic effects on cells involved in inflamma-
tion seem to be related to its ability to disrupt microtubules
and to concentrate in leukocytes, especially granulocytes,
where its peak concentration may be more than 16 times
Table 2. Study End Points
End Point Placebo
Group
(n  60)
Colchicine
Group
(n  60)
P Value
Primary: recurrence rate
at 18 months, %
55 24 0.001*
Secondary
Symptom persistence at
72 h, %
53 23 0.001*
Remission rate at 1
week, %
48 82 0.001*
Median recurrences
(10th, 90th
percentile), n
1.0 (0.0, 3.0) 0.1 (0.0, 1.0) 0.001
Median time to first
recurrence (10th,
90th percentile), mo
1.0 (0.0, 5.5) 2.5 (0.0, 19.1) 0.001
Disease-related
hospitalization, n (%)
8 (13) 3 (5) 0.20
Cardiac tamponade,
n (%)
1 (2) 0 (0) 0.99
Constrictive pericarditis,
n (%)
0 (0) 0 (0) 0.99
Mean follow-up (SD),
mo
23.7 (12.6) 21.9 (9.4) 0.38
* Calculated by using Cox regression analysis.
Figure 2. Kaplan–Meier recurrence-free survival rates, by
study group.
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the peak concentration in plasma—even at low oral doses
(2, 8). Colchicine inhibits the process of microtubule self-
assembly by binding -tubulin into tubulin–colchicine
complexes. By inhibiting the movement of intracellular
granules and the secretion of various substances, colchicine
inhibits various leukocyte functions and exhibits an anti-
inflammatory action that overcomes possible toxic effects
at low oral doses (2, 8, 13).
On the basis of limited evidence, experts have recom-
mended the use of colchicine for the treatment and pre-
vention of pericarditis (3, 8, 10, 11). Colchicine has been
proposed as a first-line treatment for recurrent pericarditis
(class I indication) and an optional treatment for acute
pericarditis (class IIa indication) in the 2004 European
guidelines on the management of pericardial diseases (14).
However, these recommendations are based on nonran-
domized studies that lacked control groups (Table 4). Two
studies published since these recommendations were made,
the COlchicine for PEricarditis (COPE) and CORE trials
(1, 4), were open-label, single-center trials. The COPE trial
(1) evaluated 120 patients and found that colchicine, 0.5
to 1 mg/d for 3 months, was an effective adjunct to con-
ventional therapy for the primary prevention of recurrent
pericarditis (rates at 18 months, 11% in the colchicine
group vs. 32% in the group that did not receive colchicine;
P  0.004; number needed to treat, 5.0) and persistence of
symptoms at 72 hours (12% vs. 37%; P  0.003). Similar
to our findings, gastrointestinal side effects were most com-
mon, and colchicine therapy was discontinued in 8% of
patients because of diarrhea. In the CORE trial (4), 84
patients who received colchicine, 0.5 to 1 mg/d for 6
months as an adjunct to conventional treatment, also had
reduced rates of recurrent pericarditis at 18 months (24%
in the colchicine group vs. 51% in the group that did not
receive colchicine; P  0.022; number needed to treat, 4.0
[CI, 2.5 to 7.1]) and persistence of symptoms at 72 hours
(10% vs. 31%; P  0.029).
Current guidelines recommend colchicine dosages of 2
mg/d for 1 to 2 days, followed by a maintenance dose of 1
mg/d. The CORE and COPE trials used a maintenance
dose of 0.5 mg twice daily, which was reduced to 0.5 mg/d
in patients weighing less than 70 kg; thus, lower doses may
be equally effective and have a lower rate of side effects.
The CORP trial confirms the previously shown benefits of
colchicine for preventing recurrent pericarditis when used
at lower doses by demonstrating similar efficacy and
tolerability.
Our study has limitations. Our findings might not be
generalizable to other settings or other patient populations.
The CORP trial addressed the use of colchicine only after
the first recurrence of pericarditis and not in patients who
had already had multiple recurrences. We also excluded
patients with elevated aminotransferase or creatinine levels,
severe liver disease, myopathy, blood dyscrasias, or gastro-
intestinal disease. Our results should not be applied to
women who are pregnant or lactating or those in their
childbearing years and who are not using sufficient contra-
ception. Because we recruited only adults, our results do
not apply to children. We also excluded patients with bac-
terial or neoplastic pericarditis; thus, the efficacy and safety
of colchicine has been shown only in a well-defined group
of patients with recurrent pericarditis. Of note, colchicine
is not approved for the prevention of pericarditis in North
America or Europe, and its use as such is off-label. Finally,
although we found a significant reduction in our primary
and secondary outcomes, our limited sample size might
have precluded the identification of certain adverse effects.
Table 3. Overall Incidence and Types of Adverse Effects
Adverse Effect Placebo Group
(n  60), n (%)
Colchicine Group
(n  60), n (%)
Overall 4 (7) 4 (7)
Gastrointestinal intolerance* 3 (5) 4 (7)
Hepatoxicity† 1 (2) 0 (0)
Myotoxicity 0 (0) 0 (0)
Alopecia 0 (0) 0 (0)
Other 0 (0) 0 (0)
Severe side effects 0 (0) 0 (0)
Drug withdrawal 4 (7) 5 (8)
Physician decision 4 (7) 4 (7)
Patient decision 0 (0) 1 (2)
* Diarrhea, nausea, cramping, abdominal pain, or vomiting.
† Any elevation of aminotransferase levels above the normal reference range.
Table 4. Main Published Studies on the Use of Colchicine to Treat Recurrent Pericarditis
Study, Year
(Reference)
Study Design Patients,
n*
Maintenance
Dosage, mg/d
Adjunct to
Standard Therapy
Follow-up,
mo
Recurrence Rate,
n/N (%)
Guindo et al, 1990 (5) Nonrandomized, case series 9 1.0 Yes 10–54 0/9 (0)
Adler et al, 1994 (6) Nonrandomized, case series 8 1.0 Yes 18–34 0/8 (0)
Millaire et al, 1994 (7) Nonrandomized, case series 19 1.0 No 32–44 4/19 (21)
Adler et al, 1998 (2) Nonrandomized, case series 51 1.0 Yes 6–128 7/51 (14)
Imazio et al, 2005 (13) Nonrandomized, case series 35 1.0 Yes 48–108 3/35 (9)
Imazio et al, 2005 (4) Randomized, open-label, single-center 84† 0.5–1.0 Yes 8–44 9/42 (21) vs. 19/42 (45)‡
* All patients had recurrent pericarditis.
† Only patients having a first recurrence of pericarditis were recruited.
‡ Recurrence rate at 18 mo: 24% vs. 51% (P  0.02).
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Several items require further investigation. First, the
specific mechanism by which colchicine prevents pericar-
ditis requires further clarification in both basic and clinical
research. Second, although colchicine therapy seems prom-
ising for recurrent pericarditis, additional research is
needed to clarify its possible use for an initial acute episode
of pericarditis. The ICAP (Investigation on Colchicine for
Acute Pericarditis) trial, a multicenter, double-blind, ran-
domized trial, should provide further evidence for or
against this indication (15). Third, a sustained anti-
inflammatory effect of colchicine may be beneficial in
forms of pericarditis that are related to autoimmune patho-
geneses, but it remains unclear whether interference of col-
chicine with leukocyte function may delay the clearance of
causative pathogens in infectious causes of pericarditis,
such as a virus. Finally, further research is needed to iden-
tify the best duration of colchicine treatment. Because re-
currences have been described after discontinuation of col-
chicine therapy, some investigators (16–20) advocate
longer use: up to 12 to 24 months after the last recurrence,
tailored to each patient, with gradual tapering in more
severe cases of recurrent pericarditis.
In summary, adding colchicine to empirical anti-
inflammatory therapy seems to be an inexpensive and safe
means to hasten symptom resolution, improve remission
rates by 1 week, and reduce recurrence after an initial re-
currence of pericarditis.
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